Topic Hub
13 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 13 of 13 clinical reviews.
A clinical guide to Leqvio (inclisiran) subcutaneous injection for patients 65+, covering caregiver technique, storage, missed-dose rules, and safety monitoring in older adults.
Read clinical reviewA clinician-reviewed guide to inclisiran use in adults 65 and older, covering physical activity safety, cardiac rehabilitation, fall risk, injection scheduling, and how older patients can maintain active lives while on twice-yearly PCSK9 inhibitor therapy.
Read clinical reviewA comprehensive clinical guide to how inclisiran (Leqvio) affects growth, puberty, hormones, and long-term development in adolescents ages 12 to 17 with heterozygous familial hypercholesterolemia.
Read clinical reviewA comprehensive clinical review of inclisiran (Leqvio) use in adolescents ages 12 to 17, covering the off-label rationale, available pediatric trial data, dosing considerations, safety signals, and how clinicians are weighing it against approved alternatives for familial hypercholesterolemia.
Read clinical reviewA clinical deep-dive into how inclisiran (Leqvio) performs in patients aged 65 and older, covering efficacy, safety, pharmacokinetics, dosing, and cardiovascular outcomes data from ORION trials and post-marketing evidence.
Read clinical reviewA physician-reviewed guide to inclisiran (Leqvio) use in patients aged 65 and older, covering trial evidence, safety data, renal and hepatic considerations, and clinical decision-making for geriatric ASCVD management.
Read clinical reviewA clinical guide to using inclisiran (Leqvio) in adults aged 65 and older, covering dosing, safety, ORION trial data, polypharmacy interactions, and practical handoff from younger-adult protocols.
Read clinical reviewComplete caregiver guide for Leqvio (inclisiran) in children under 12, covering FDA approval status, HoFH trial data, injection technique, storage, and what to expect at each clinic visit.
Read clinical reviewHow adolescents aged 12 to 17 taking inclisiran (Leqvio) for heterozygous familial hypercholesterolemia should transition to adult lipid care, including dosing continuity, monitoring schedules, and shared decision-making frameworks.
Read clinical reviewComplete caregiver guide to administering Leqvio (inclisiran) to adolescents aged 12-17 with HeFH: injection technique, dosing schedule, storage, side-effect management, and when to call the clinic.
Read clinical reviewA practical guide for teens and parents on how inclisiran (Leqvio) injections fit into school schedules, physical activity, and daily life, with clinical evidence and dosing details.
Read clinical reviewA clinical guide to transitioning pediatric patients under age 12 on inclisiran (Leqvio) into adult lipid management programs, including dosing considerations, monitoring schedules, and guideline-based care pathways.
Read clinical reviewA clinical guide for parents and pediatric care teams on managing inclisiran (Leqvio) dosing schedules, physical activity, and school routines in children under 12 with familial hypercholesterolemia.
Read clinical review